Leaflet ALKERAN 2mg film-coated tablets


Indicated for: cancer

Route of administration: oral

Substance: melphalan (alkylating antineoplastic agent)

ATC: L01AA03 (Antineoplastic and immunomodulating agents | Alkylating agents | Nitrogen mustard analogues)

Melphalan is a chemotherapy agent primarily used to treat certain types of cancer, such as multiple myeloma and ovarian cancer. It works by interfering with the DNA of cancer cells, preventing them from dividing and spreading.

Melphalan is administered either orally or intravenously, depending on the type and stage of cancer being treated. The treatment may be associated with side effects such as nausea, vomiting, decreased blood cell counts, and an increased risk of infections.

Patients undergoing melphalan treatment must be closely monitored by their doctor to assess effectiveness and manage any adverse reactions. It is important to strictly follow the prescribed doses.

This medication is used only under strict medical supervision and is not recommended for pregnant or breastfeeding women due to risks to the fetus or child.

General data about ALKERAN 2mg

  • Substance: melphalan
  • Date of last drug list: 01-05-2026
  • Commercial code: W58865001
  • Concentration: 2mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 25
  • Product type: original
  • Price: 105.38 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: EXCELLA GMBH - GERMANIA
  • Holder: ASPEN PHARMA TRADING LIMITED - IRLANDA
  • Number: 11742/2019/01
  • Shelf life: 2 years

Concentrations available for melphalan

  • 200mg
  • 2mg
  • 50mg

Compensation lists for ALKERAN 2mg Aspen

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

105.38 RON

105.38 RON

0.00 RON

NHP 9.1 (C2) - Spinal cord transplant

Price

Copayment

Patient

105.38 RON

105.38 RON

0.00 RON